Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma

Pediatric Blood and Cancer

Volumn 49, Issue 7, 2007, Pages 952-957

  Cai, Jiao Yang ^a   Tang, Yan Jing ^a   Jiang, Li Min ^a   Pan, Ci ^a   Chen, Jing ^a   Tang, Jing Yan ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Flow cytometry; Minimal residual disease; Neuroblastoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CELL SELECTION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFANT; MAGNETIC ACTIVATED CELL SEPARATION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; SEPARATION TECHNIQUE; TREATMENT RESPONSE;

ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RECURRENCE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 35649020637     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21253     Document Type: Article

References (25)

1. Kushner BH, Cheung NK. What factors predict a favorable outcome in young children with disseminated neuroblastoma? Nat Clin Pract Oncol 2006;3:242-243.
2. Nagai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol 2000;22:20-26.
3. Tsang KS, Li CK, Tsoi WC, et al. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer 2003;97:2887-2897.
4. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006;24:2891-2896.
5. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005;6:649-658.
6. Marcus KJ, Shamberger R, Litman H, et al. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003;25:934-940.
7. Imaizumi M, Watanabe A, Kikuta A, et al. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: A retrospective analysis from the Tohoku Neuroblastoma Study Group. Tohoku J Exp Med 2001;195:73-83.
8. Choi HS, Koh SH, Park ES, et al. CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma. Pediatr Blood Cancer 2005;45:68-71.
9. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34 selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858-1868.
10. Warzynski MJ, Graham DM, Axtell RA, et al. Flow cytometric irnmunophenotyping test for staging/monitoring neuroblastoma patients. Cytometry 2002;50:298-304.
11. Watanabe T, Murakumo Y, Murakami H, et al. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 2002;161:249-256.
12. Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994;12:28-36.
13. Fukuda M, Miyajima Y, et al. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: A pilot study. J Pediatr Hematol Oncol 2001;23:10-13.
14. Susan AB, Sally EK, Susan P, et al. Minimal residual disease at the time of peripheral blood stem cell harvest inpatients with advanced neuroblastoma. Med Pediatr Oncol 2001;36:213-219.
15. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24:500-506.
16. Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther 2005;5:835-846.
17. Donovan J, Temel J, Zuckerman A, et al. CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies. Med Pediatr Oncol 2000;35:677-682.
18. Rowley SD, Loken M, Radich J, et al. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplant 1998;21:1253-1262.
19. Handgretinger R, Lang P, Schum M, et al. Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting. Bone Marrow Transplant 1998;21:987-993.
20. Ryu KH, Ahu HS, Koo HH, et al. Autologous stem cell transplantation for the treatment of neuroblastoma in Korea. J Korean Med Sci 2003;18:242-247.
21. Lode HN, Handgretinger R, Schuermann U, et al. Detection of neuroblastoma cells in CD34+ selection peripheral stemcells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 1997;33:2024-2030.
22. Burchill SA. Micrometastases in neuroblastoma: Are they clinically important? J Clin Path 2004;57:14-20.
23. Gupta D, Bybee A, Cooke F, et al. CD34 selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: Tumour cell contamination and outcome. Br J Haematol 1999;104:166-177.
24. Tchirkov A, Kanold J, Giblant MJ, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998;30:228-232.
25. Shimoni A, Körbling M. Tumor cell contamination in re-infused stem cell autografts: Does it have clinical significance? Crit Rev Oncol/Hematol 2002;41:241-250.